N-苄基-2-(4-苄基-1H-1,2,3-三唑-1-基)-4-甲基噻唑-5-甲酰胺 | 1034981-60-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: N-苄基-2-(4-苄基-1H-1,2,3-三唑-1-基)-4-甲基噻唑-5-甲酰胺
• 英文名称: N-benzyl-2-(4-benzyl-1H-1,2,3-triazol-1-yl)-4-methylthiazole-5-carboxamide
• 英文别名: N-benzyl-2-(4-benzyltriazol-1-yl)-4-methyl-1,3-thiazole-5-carboxamide
• CAS: 1034981-60-6
• 化学式: C₂₁H₁₉N₅OS
• 分子量: 389.481
• InChiKey: FCNRROILAPCDRL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  101
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-azido-N-benzyl-4-methylthiazole-5-carboxamide 、 苯乙炔 在 copper(l) iodide 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 N-苄基-2-(4-苄基-1H-1,2,3-三唑-1-基)-4-甲基噻唑-5-甲酰胺
  参考文献：
  名称：

  Systematic evaluation of amide bioisosteres leading to the discovery of novel and potent thiazolylimidazolidinone inhibitors of SCD1 for the treatment of metabolic diseases

  摘要：

  Several five- and six-membered heterocycles were introduced to replace the C2-position amide bond of the original 2-aminothiazole-based hit compound 5. Specifically, replacement of the amide bond with an imidazolidinone moiety yielded a novel and potent thiazolylimidazolidinone series of SCD1 inhibitors. XEN723 (compound 22) was identified after optimization of the thiazolylimidazolidinone series. This compound demonstrated a 560-fold improvement in in vitro potency and reduced plasma desaturation indices in a dose dependent manner, with an EC50 of 4.5 mg/kg. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.036

文献信息

• ORGANIC COMPOUNDS
  申请人：Dales Natalie

  公开号：US20100029722A1

  公开（公告）日：2010-02-04

  The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了可以调节硬脂酰辅酶A去饱和酶活性的杂环衍生物。还包括使用这些衍生物来调节硬脂酰辅酶A去饱和酶活性的方法和包含这些衍生物的药物组合物。
• SCD1 inhibitors triazole and tetrazole compounds
  申请人：Novartis AG

  公开号：US08258160B2

  公开（公告）日：2012-09-04

  The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

  本发明提供了调节硬脂酰辅酶A去饱和酶活性的杂环衍生物。还涵盖了使用这些衍生物来调节硬脂酰辅酶A去饱和酶活性的方法以及包含这些衍生物的药物组合物。
• 2-SUBSTITUTED 5-MEMBERED HETEROCYCLES AS SCD INHIBITORS
  申请人：Novartis AG

  公开号：EP2121671A1

  公开（公告）日：2009-11-25
• US8258160B2
  申请人：——

  公开号：US8258160B2

  公开（公告）日：2012-09-04
• [EN] 2-SUBSTITUTED 5-MEMBERED HETEROCYCLES AS SCD INHIBITORS<br/>[FR] COMPOSÉS ORGANIQUES
  申请人：NOVARTIS AG

  公开号：WO2008074835A1

  公开（公告）日：2008-06-26

  [EN] The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.
  [FR] La présente invention porte sur des dérivés hétérocycliques modulant l'activité de la stéaroyl-CoA désaturase. L'invention concerne également des procédés d'utilisation de ces dérivés pour moduler l'activité de la stéaroyl-CoA désaturase et des compositions pharmaceutiques comprenant de tels dérivés.